Beta Bionics, Inc. BBNX
Nov 11, 2026, 1:19 PM EST
- YTD
- -42.37%
- 1 year
- -39.07%
- Market cap
- 955.77M
- Revenue (ttm)
- 119.01M
- Profit margin
- -61.31%
- EPS (ttm)
- -1.83
- Shares out
- 53.95M
- Forward P/E
- -9.90
- YTD return
- -42.37%
- 1-year return
- -39.07%
- Volume
- 424.51K
- Avg volume
- 1.23M
- Open
- 16.77
- Previous close
- 16.52
- Day's range
- 16.77 – 17.79
- 52-week range
- 8.80 – 32.71
- Price target
- 24.24 (+38.1%)
- Earnings date
- Feb 16, 2027
5D +0.60 (+3.77%)
Key statistics
- Enterprise value
- 748.76M
- PEG ratio
- 0.00
- Price / sales
- 9.70
- Price / book
- 3.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 37.80%
- Free cash flow
- -40.29M
- Total cash
- 180.49M
- Total debt
- 6.51M
- Return on equity
- -26.16%
- Short % of float
- 11.25%
- 50-day average
- 19.16
- 200-day average
- 14.81
Analyst view
- Target (low)
- 16.00
- Target (mean)
- 24.24
- Target (high)
- 30.40
- Strong buy2
- Buy9
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -0.51333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -0.49 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | -0.52334 | -0.52 | 0.00 | +0.64% |
| Jul 29, 2026 | Jun 30, 2026 | -0.58103 | -0.53 | +0.05 | +8.78% |
| Apr 21, 2026 | Mar 31, 2026 | -0.53 | -0.49 | +0.04 | +7.55% |
| Feb 17, 2026 | Dec 31, 2025 | -0.42 | -0.30 | +0.12 | +28.57% |
| Oct 28, 2025 | Sep 30, 2025 | -0.45 | -0.33 | +0.12 | +26.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | init | — | Buy |
| Sep 24, 2026 | Truist Securities | main | Buy | Buy |
| Sep 23, 2026 | Wells Fargo | init | — | Overweight |
| Sep 15, 2026 | B of A Securities | main | Neutral | Neutral |
| Sep 15, 2026 | Truist Securities | reit | Buy | Buy |
| Sep 15, 2026 | Baird | main | Neutral | Neutral |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- betabionics.com
News
Beta Bio: 3 Key Takeaways for Long-Term Investors 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21 
Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24 
Beta Bionics Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est - Beta Bionics Q3 EPS $(0.52) Beats $(0.53) Estimate, Sales $35.505M Beat $34.722M Estimate
- Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Your note
Sign in to keep a note on BBNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARNEY SEAN D | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| DEAREN DANNY L | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| FEIDER STEPHEN | Chief Financial Officer | Sale | Sep 1, 2026 | 159,378 |
| HOPMAN MARK | Officer | Sale | Sep 30, 2026 | 56,109 |
| MENSINGER MIKE | Officer | Sale | Sep 15, 2026 | 177,390 |
| MICHEL GERARD J | Director | Stock Award(Grant) | May 20, 2026 | 33,509 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eventide Asset Management LLC | 13.90% | 6,253,673 | 133.77M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 9.77% | 4,393,714 | 93.98M | Jun 29, 2026 |
| Morgan Stanley | 9.48% | 4,266,822 | 91.27M | Jun 29, 2026 |
| Sands Capital Alternatives, LLC | 8.24% | 3,708,043 | 79.32M | Jun 29, 2026 |
| Blackrock Inc. | 7.42% | 3,340,171 | 71.45M | Jun 29, 2026 |
| Point72 Asset Management, L.P. | 5.01% | 2,254,683 | 48.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 8.86% | 3,983,917 | 85.22M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 4.56% | 2,052,176 | 43.90M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.83% | 1,272,504 | 27.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.35% | 1,055,217 | 22.57M | Sep 29, 2026 |
| Bruce Fund, Inc.-BRUCE FUND | 1.48% | 665,700 | 14.24M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.04% | 469,615 | 10.05M | Jun 29, 2026 |